ARC1779

Archemix Announces Completion of Phase 1 Trial of ARC1779

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - Archemix Corp., a biotechnology company focused on discovering and developing aptamers, announced the successful completion of a Phase 1 study of its novel aptamer therapeutic, ARC1779. ARC1779 is designed to selectively block the activation, adhesio...

ARC1779 in other areas

Archemix : Products : ARC1779 in TMA

We believe that ARC1779 can bind to and inhibit the activity of ... In March 2007, we completed a Phase 1 clinical trial of ARC1779 in 47 healthy volunteers. ...

Archemix : Products : Product Pipeline

Our aptamer product candidate, ARC1779, is a PEGylated aptamer consisting of 40 ... We believe that ARC1779, with its potential to inhibit the function of vWF, ...

Archemix' ARC1779 Granted Orphan Designation in EU for the Treatment of ...

ARC1779, a novel aptamer therapeutic, is a first-in-class anti-platelet agent ... ARC1779 is designed to bind to and inhibit a protein known as von Willebrand ...

Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing ...

To determine the effect of ARC1779 on the incidence of new ischemic lesions ... To assess the relationships among ARC1779 PD, PK, and the frequency of cerebral ...

Portfolio Company News

ARC1779 is an novel aptamer therapeutic designed to bind to and inhibit vWF, ... This Phase 2 trial of ARC1779 in TTP is being conducted at the Medical ...

Archemix Initiates Phase 2a for Lead Aptamer Product Candidate ARC1779

Company Achieves Key Clinical Milestone with Initiation of Second Phase 2 Trial for ARC1779 ... the pharmacokinetic and pharmacodynamic profile of ARC1779. ...